Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Shares Up After Lymphoma Study Meets Objectives

06/10/2021 | 09:09am EDT

By Michael Dabaie

Bristol Myers Squibb Co. shares were 3% higher to $67.22 in morning trading after a Phase 3 study in lymphoma met its main objective.

The company said before the market open that a Phase 3 study of Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma met its primary and key secondary objectives.

"We ambitiously designed the TRANSFORM trial to evaluate Breyanzi's potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard of care regimen of high-dose chemotherapy and autologous stem cell transplant," said Noah Berkowitz, senior vice president of hematology and cell therapy development for Bristol Myers.

This represents the first time a therapy has demonstrated benefit compared with high-dose chemotherapy and stem cell transplant in relapsed or refractory large B-cell lymphoma, Bristol Myers said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

06-10-21 1109ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.45% 66.47 Delayed Quote.7.16%
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
All news about BRISTOL-MYERS SQUIBB COMPANY
06/18BRISTOL MYERS SQUIBB  : Secures European Approval for Onureg in Acute Myeloid Le..
MT
06/18BRISTOL MYERS SQUIBB  : Receives European Commission Approval for Onureg® (azaci..
BU
06/18Bristol Myers Gets EC Approval for Onureg in Acute Myeloid Leukemia
DJ
06/18BRISTOL MYERS SQUIBB  : Eisai Team up to Develop, Market Anticancer Drug Candida..
MT
06/18NIKKEI 225  : Off 0.2% on Afternoon Slump
MT
06/17BRISTOL MYERS SQUIBB  : Eisai and Bristol Myers Squibb Enter Into Global Strateg..
BU
06/17BRISTOL MYERS SQUIBB  : Keeps Dividend at $0.49 a Share; Payable August 2 to Sha..
MT
06/17BRISTOL MYERS SQUIBB  : Announces Dividend
BU
06/14Exelixis in Clinical Trial Collaboration with Bristol Myers
DJ
06/14Exelixis Working With Bristol-Myers to Launch Early-Stage Study of Potential ..
MT
More news
Financials (USD)
Sales 2021 46 106 M - -
Net income 2021 7 116 M - -
Net Debt 2021 26 832 M - -
P/E ratio 2021 20,9x
Yield 2021 2,93%
Capitalization 148 B 148 B -
EV / Sales 2021 3,80x
EV / Sales 2022 3,44x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 75,24 $
Last Close Price 66,47 $
Spread / Highest target 35,4%
Spread / Average Target 13,2%
Spread / Lowest Target -6,72%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY7.16%148 417
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795